Expert Opinion on Pharmacotherapy

Article	Citations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	36
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	36
The pharmacological treatment and management of hyperhidrosis	35
Fixed-dose combination amlodipine–celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation	32
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	30
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	29
Bexagliflozin for type 2 diabetes: an overview of the data	28
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	28
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	27
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	27
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	26
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	25
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	24
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	24
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	23
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	23
Current treatment options for Mycobacterium marinum cutaneous infections	22
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	20
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	19
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	19
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?	19
How useful is chemotherapy for atypical and anaplastic meningiomas?	19
Zanubrutinib for the treatment of chronic lymphocytic leukemia	18
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	18
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	18

An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	18
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	18
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	17
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	16
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	16
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	16
Correction	16
Rise and fall of decongestants in treating nasal congestion related diseases	15
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	14
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	14
Momelotinib in myelofibrosis	14
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	14
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	13
Current advancements in pharmacotherapy for cancer cachexia	13
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	12
Treating pediatric aggressive behaviors and comorbid conditions	12
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	12
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	12
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	11
Upadacitinib in Crohn’s disease	11
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	11
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	11
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	11
Tirzepatide for overweight and obesity management	11
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	11
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	10
Current pharmacological solutions for Behçet’s syndrome	10
Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer	10
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	10
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	10
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	10
Correction	10
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	10
Advances in the management of urothelial carcinoma: is immunotherapy the answer?	10
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	10
Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review	10
An update on current pharmacotherapy for vulvar cancer	10
Recent progress in the use of pharmacotherapy for endometrial cancer	10
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	10
The treatment of advanced lung adenocarcinoma with activating EGFR mutations	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	9
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	9
Use of glucagon-like polypeptide 2 analogs for intestinal failure	9
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	9
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	9
An overview of emergency pharmacotherapy for priapism	9
Advances in pharmacotherapy for neuroblastoma	9
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	9
Simnotrelvir as a potential treatment for COVID-19	9
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	9

Pharmacogenomics and pediatric drug development: science and political power. A narrative review	9
Modern pharmacotherapy guidance for treating alcohol use disorders	9
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	9
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	9
Pharmacological management of pituitary adenomas – what is new on the horizon?	9
Evidence-based prescribing of medications for ADHD: where are we in 2023?	9
Drug treatment strategies for eosinophilic esophagitis in adults	9
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	9
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	9
An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection	9
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	9
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	9
Advances with androgen deprivation therapy for prostate cancer	9
The role of sulfonylureas in the treatment of type 2 diabetes	9
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	8
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	8
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	8
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	8
Pharmacotherapy for artemisinin-resistant malaria	8
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	8
Advances in the pharmacotherapeutic management of refractory peptic ulcers	8
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease	8
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	8
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	8
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	8
Pharmaceutical advances in the treatment of gastric adenocarcinoma	8
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	8
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes	8
Migraine in multiple sclerosis patients: potential links and treatment approach	7
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	7
An update on the pharmacological management of acne vulgaris: the state of the art	7
An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date	7
Evaluating fostemsavir as a therapeutic option for patients with HIV	7
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	7
How do we address treating the negative symptoms of schizophrenia pharmacologically?	7
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	7
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	7
Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy?	7
Reassessing the role of aspirin in patients with coronary artery disease	7
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	7
The management of cardiovascular disease risk in patients with rheumatoid arthritis	7
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	7
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	7
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	7
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	7
Can NSAIDs and Acetaminophen Effectively Replace Opioid Treatment Options for Acute Pain?	7
Recently approved and emerging drug options for migraine prophylaxis	7
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	7
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	7
Current status of intracavernosal injection therapy in erectile dysfunction	7
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	7
Pharmacotherapeutic options for the treatment of menopausal symptoms	7
Addressing the long-term risks of administering antenatal steroids	7
Pharmacological treatment for children with constipation: present and future	7
Protein kinase inhibitors for the treatment of prostate cancer	7
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes	7
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	7
Managing dyslipidemia in patients with Type 2 diabetes	7
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	6
An update on the pharmacotherapy of gout	6
Azole resistance in Aspergillus species: promising therapeutic options	6
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	6
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	6
Advances in the pharmacological management of acute myeloid leukemia in adults	6
Pharmacological strategies for improving the prognosis of glioblastoma	6
Guidance for the pharmacological management of COVID-19 in the emergency setting	6
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease	6
Risk management of medication errors: a novel conceptual framework	6
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	6
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	6
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes	6
Evaluating upadacitinib for the treatment of psoriatic arthritis	6
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	6
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	6
Glasdegib for the treatment of acute myeloid leukemia	6
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	6
Promising therapies for the treatment of acromegaly	6
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	6
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	6
Upadacitinib in Crohn’s disease: needs more insight	6

An update on antifungal resistance in dermatophytosis	6
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	6
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	6
Pharmacological management of migraine: current strategies and future directions	6
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	6
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	6
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	6
The pharmacological management of treatment-resistant depression: what does the future hold?	6
How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?	6
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	6
Advances in pharmacotherapy for bronchiectasis in adults	6
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	6
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	6
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	6
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	6
Liposomal drug formulations for treatment of hematological malignancies	5
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	5
State-of-the-art and emerging antivirals for chronic hepatitis B infection	5
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	5
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	5
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	5
How far are we from an approved drug for nonalcoholic steatohepatitis?	5
Pharmacological management of heart failure: a patient-centred approach	5
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	5
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	5
Advances in pharmacotherapy for diabetic foot osteomyelitis	5
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	5
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	5
Novel pharmacotherapy for drug-induced immune hemolytic anemia	5
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	5
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	5
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	5
The evolving atopic dermatitis management landscape	5
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	5
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	5
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	5
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs	5
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	5
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	5
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	5
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	5
A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan	5
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	5
Polypharmacology of carbonic anhydrase inhibitors and activators	5
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	5
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	5
The pharmacological management of alcohol-related cirrhosis: what’s new?	5
Current factor IX replacement options for hemophilia B and the challenges ahead	5
Can cannabinoids still play a role as pain medications?	5
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	5
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	5
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	5
Paxlovid as a potential treatment for long COVID	5
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	4
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions	4
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	4
A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies	4
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	4
Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain	4
Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy	4
Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?	4
An update on the pharmacological management of acute respiratory distress syndrome	4
Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?	4
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis	4
Management of non-alcoholic fatty liver disease in patients with sarcopenia	4
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine	4
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	4
Doravirine/islatravir for the treatment of HIV	4
An update on inclisiran for the treatment of elevated LDL cholesterol	4
An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China	4
Montelukast as a potential treatment for COVID-19	4
Advances in pharmacotherapy for rosacea: what is the current state of the art?	4
Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?	4
A pharmacoeconomic evaluation of the pharmacotherapeutic options for painful diabetic neuropathy	4
Immunosuppression in uterus transplantation: from transplant to delivery	4
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer	4
Pharmacotherapy for post-stroke aphasia: what are the options?	4
An update on pharmacotherapies for colorectal cancer: 2023 and beyond	4
New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview	4
Valbenazine for the treatment of chorea associated with Huntington’s disease	4
What are the challenges in the pharmacotherapeutic management of male genital tuberculosis?	4
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	4
Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?	4
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	4
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data	4
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	4
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors	4
Pharmaceutical management of sexual dysfunction in men on antidepressant therapy	4
New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality	4
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy	4
Advances in pharmacotherapy for head and neck cancer	4
The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration	4
Advances in pharmacotherapy for acute and recurrent pericarditis	4
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	4
Can we effectively manage binge eating disorder with pharmacotherapy?	4